mk 0493
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2004 (NCT00482638)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanocortin receptor 4AGONIST
MC4R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mk0493
- mk0493
- mk0493
- mk 0493
- mk-0493
- n-1-(2-(1-(tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl)-5-chlorophenyl)ethyl)acetamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00482196 | Phase 2 | Jul 1, 2005 | Merck |
| NCT00482638 | Phase 2 | May 1, 2004 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 1 | 2004 |
1 organizations
Page 1 / 1